Asymmetry Synthesis: Powerful Tool for The Pharmaceutical Industry
Gabrielle Pedroso da Silva1, Leonardo Pizol Ferreira1, Gustavo Elias Arten
Isaac2 and Renan Marcel Bonilha Dezena3,4*
1University Center of the Octávio Bastos Teaching Foundation (UNIFEOB), Department of Pharmaceutical Science, Brazil
2University Center of the Octávio Bastos Teaching Foundation (UNIFEOB), Faculty of Pharmacy, Professor, Brazil
3University Center of the Octávio Bastos Teaching Foundation (UNIFEOB), Faculty of Pharmacy, Expert Collaborator, Brazil
4Preformulation Specialist in The Pharmaceutical Industry, Brazil
*Corresponding Author: Renan Marcel Bonilha Dezena, University Center of the Octávio Bastos Teaching Foundation (UNIFEOB), Faculty of Pharmacy, Expert
Collaborator and Preformulation Specialist in The Pharmaceutical Industry, Brazil.
Received:
January 19, 2023; Published: January 25, 2023
Abstract
Background
The understanding of how a chemical substance, used as a drug, exerts its activity within the body, it must be taken into account that the three-dimensional structure of this drug has fundamental importance in the biological receptor, because the format of a drug molecule must be complementary to its receptor site, just as a key is complementary to the lock, so that, through chemical bonds, they bind properly and generate the expected biological response [1,2].
References
- Mansour MA., et al. “Highlights on selected growth factors and their receptors as promising anticancer drug targets”. The International Journal of Biochemistry and Cell Biology 140 (2021): 1060-1087.
- Tripathi A and Bankaitis VA. “Molecular Docking: From Lock and Key to Combination Lock”. Journal of Molecular Medicine and Clinical Applications 1 (2017): 1-19.
- Naveen Chhabra., et al. “A review of drug isomerism and its significance”. International Journal of Applied and Basic Medical Research 1 (2013): 16-18.
- Brooks WH., et al. “The significance of chirality in drug design and development”. Current Topics in Medicinal Chemistry 7 (2011): 760-770.
- Atkins P., et al. “Chemical Principles: The Quest For Insight”. Bookman Editorial (2018).
- Katzung BG and Trevor AJ. “Basic and Clinical Pharmacology”. Lange Medical Publications (2017).
- Roberts JS., et al. “R-etodolac is a more potent Wnt signaling inhibitor than enantiomer, S-etodolac”. Biochemistry and Biophysics Reports 30 (2022): 1-6.
- Benez FHN., et al. “Comparative study of anti-inflammatory, ulcerogenic and cytotoxic activities of racemate and S-ibuprofen”. Journal of Basic and Applied Pharmaceutical Sciences 3 (2013): 327-332.
- Dalal J., et al. “S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine”. International Journal of Hypertension 2018 (2018): 1-14.
- Papp LA., et al. “Determination of Chiral Impurity of Naproxen in Different Pharmaceutical Formulations Using Polysaccharide-Based Stationary Phases in Reversed-Phased Mode”. Molecules 9 (2022): 1-13.
- Estrada-Valenzuela D., et al. “Lipase Assisted (S)-Ketoprofen Resolution from Commercially Available Racemic Mixture”. Pharma 10 (2021): 1-10.
- Pandya PA., et al. “Simultaneous enantioseparation and simulation studies of atenolol, metoprolol and propranolol on Chiralpak® IG column using supercritical fluid chromatography”. Journal of Pharmaceutical Analysis 6 (2021): 746-756.
- Harvison PJ. “Warfarin”. xPharm: The Compr. Pharmacol. Ref. (2007): 1-7.
- Passie T., et al. “Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers”. European Neuropsychopharmacology 44 (2021): 92-104.
Citation
Copyright